The heart-drug Multaq® , which an FDA report has linked to severe liver injuries , is now being cited for additional safety issues.
The independent Institute for Safe Medicine Practices, in its quarterly update on drug safety, reports that Multaq (dronedarone) was associated with more cases of slow heart beat; a rapid heart beat in the heart’s main chamber, and an uncontrolled arrhythmia in the atria than all other drugs the institute monitors. (See full story by Pharmalot).
The drug, sold by Sanofi-Aventis, is designed to prevent potentially deadly arrhythmia and make the heart beat normally.
The FDA on January 4 of this year already issued a warning to healthcare providers, noting that it was aware of two women taking Multaq who suffered acute liver failure that required liver transplants.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.